All In Biotech

Drug Trial Radar · NCT06706713

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 15, 2022

Primary completion

Dec 31, 2025

Study completion Jun 30, 2026

Sponsor

Lead sponsor
BeBetter Med IncIndustry
Sponsor type
Industry
First posted
Nov 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Conditions

  • Non-Small Cell Lung Cancer
  • EGFR Exon 20 Insertion Mutation

Interventions

  • BEBT-109 CapsuleDrug

    Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Every 8 weeks,assessed up to 24 months.
  2. PFSTime frame: Every 8 weeks,assessed up to 24 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.